A case of a female patient with thalidomide-induced phocomelia and additional dermal complications associated with the prosthesis itself is presented herein.
[3] Stephens TD, Bunde CJW, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharm 2000; 59: 1489–1499 http://dx.doi.org/10.1016/S0006-2952(99)00388-3[Crossref]
[4] Schuler-Faccini L, Soares RC, de Sousa AC, et al. New cases of thalidomide embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol 2007; 79: 671–672 http://dx.doi.org/10.1002/bdra.20384[Crossref]
[5] Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005; 10: 107–114 http://dx.doi.org/10.1016/S1359-6446(04)03307-0[Crossref]
[6] Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin 2010; 28:577–586 http://dx.doi.org/10.1016/j.det.2010.03.003[Crossref][WoS]
[7] Legro MW, Reiber G, del Aguila M et al. Issues of importance reported by persons with lower limb amputations and prostheses. J Rehabil Res Dev 1999; 36:155–163
[8] Cochrane H, Orsi K, Reilly P. Lower limb amputation. Part 3: Prosthetics-a 10 year literature review. Prosthet Orthot Int 2001; 25:21–28 http://dx.doi.org/10.1080/03093640108726564[Crossref]